<DOC>
	<DOCNO>NCT00187096</DOCNO>
	<brief_summary>The purpose study assess safety efficacy infuse natural killer cell donor treatment patient acute myeloid leukemia remission experience relapse .</brief_summary>
	<brief_title>Natural Killer ( NK ) Cell Transplantation AML</brief_title>
	<detailed_description>Natural killer ( NK ) cell extract [ parental ] donor infuse intravenously . Most patient give multi-agent chemotherapeutic conditioning regimen prior infusion . The condition regimen may omit patient previously receive traditional stem cell transplant . Details Treatment Plan : Stratum 1 ( AML complete remission ) Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 -2 Donor pheresis Day -1 Start IL-2 Day -1 , 3 time per week x 2 week NK Cell purification infusion Day 0 Stratum 2 ( AML refractory relapse AML increase minimal residual disease ) Clofarabine 40 mg/m2 IV , day -6 -2 Etoposide 100 mg/m2 IV , day -6 -2 Cyclophosphamide 400 mg/m2 IV , day -6 02 Donor pheresis Day -1 Start IL-2 Day -1 , 3 time per week x 2 week NK Cell purification infusion Day 0 . For patient receive prior SCT , condition regimen may omit NK cell obtain original SCT donor . Cytokine regimen ( stratum 1 2 ) : 1 million units/m2 IL-2 give subcutaneously three time per week two week ( 6 dos ) start even day -1 . NK Cell Transplantation ( stratum 1 2 ) : NK cell haplo-identical family donor infuse day 0 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Participants AML complete remission , relapse refractory , increase minimal residual disease . Participants complete remission must recover toxicity previous therapy evidence bone marrow recovery Participants prior stem cell transplant ( SCT ) must evidence GVHD 60 day elapse since SCT . Participants pregnant Participants inadequate renal , liver , pulmonary function</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Acute</keyword>
</DOC>